PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study

Patients with metastatic cancer refractory to standard systemic therapies have a poor prognosis and few therapeutic options. Radiotherapy can shape the tumor microenvironment (TME) by inducing immunogenic cell death and promoting tumor recognition by natural killer cells and T lymphocytes. Granulocy...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in immunology Vol. 13; p. 952066
Main Authors:	Kong, Yuehong, Zhao, Xiangrong, Xu, Meiling, Pan, Jie, Ma, Yifu, Zou, Li, Peng, Qiliang, Zhang, Junjun, Su, Cunjin, Xu, Zhi, Zhou, Wei, Peng, Yong, Yang, Jiabao, Zhou, Chengliang, Li, Yujia, Guo, Qiuchen, Chen, Guangqiang, Wu, Hongya, Xing, Pengfei, Zhang, Liyuan
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 08.07.2022
Subjects:	Chemoradiotherapy - adverse effects chemotherapy refractory granulocyte macrophage-colony stimulating factor Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use Humans Immune Checkpoint Inhibitors - therapeutic use Immunology Neoplasms, Second Primary - therapy PD-1 inhibitor radiotherapy Salvage Therapy Treatment Outcome Tumor Microenvironment radiotherapy chemotherapy refractory PD-1 inhibitor tumor microenvironment granulocyte macrophage-colony stimulating factor
ISSN:	1664-3224, 1664-3224
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!